Grail (GRAL) Stock Price, News & Analysis

Company Overview

GRAIL, Inc. is a healthcare company. It engages in the development of a technology for early detection of cancer. The company was founded by Jeffrey T. Huber, William H. Rastetter, and Mostafa Ronaghi on September 11, 2015 and is headquartered in Menlo Park, CA.

Key Stats

• Today's Range: $37.85 to $49.00
• 50-Day Range: $17.14 to $55.02
• 52-Week Range: $12.33 to $63.99
• Volume: 2.84 million shs
• Average Volume: 1.75 million shs
• Market Capitalization: $1.37 billion
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $16.00
• Consensus Rating: Hold

Grail Stock Analysis - MarketRank™

Grail scored higher than 20% of companies evaluated by MarketBeat, and ranked 864th out of 950 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 1.0 / 5
• Analyst Rating: Hold

Consensus Rating

Grail has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no buy ratings, 3 hold ratings, and no sell ratings.

Amount of Analyst Coverage

Grail has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Grail are expected to grow in the coming year, from ($15.15) to ($12.95) per share.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

18.92% of the float of Grail has been sold short.

Short Interest Ratio / Days to Cover

Grail has a short interest ratio ("days to cover") of 5.2.

Change versus previous month

Short interest in Grail has recently decreased by 14.52%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Grail does not currently pay a dividend.

Dividend Growth

Grail does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

18.92% of the float of Grail has been sold short.

Short Interest Ratio / Days to Cover

Grail has a short interest ratio ("days to cover") of 5.2.

Change versus previous month

Short interest in Grail has recently decreased by 14.52%, indicating that investor sentiment is improving significantly.

News and Social Media

• Score: 3.8 / 5
• News Sentiment: 0.83

News Sentiment

Grail has a news sentiment score of 0.83. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.60 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 22 news articles for Grail this week, compared to 6 articles on an average week.

Search Interest

19 people have searched for GRAL on MarketBeat in the last 30 days. This is an increase of 217% compared to the previous 30 days.

MarketBeat Follows

28 people have added Grail to their MarketBeat watchlist in the last 30 days. This is an increase of 367% compared to the previous 30 days.

Company Ownership

• Score: N/A
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Grail insiders have not sold or bought any company stock.

GRAL Stock Analysis - Frequently Asked Questions

How have GRAL shares performed this year?

Grail's stock was trading at $17.85 at the beginning of 2025. Since then, GRAL shares have increased by 128.2% and is now trading at $40.73.
View the best growth stocks for 2025 here.

How were Grail's earnings last quarter?

Grail, Inc. (NASDAQ:GRAL) posted its earnings results on Thursday, February, 20th. The company reported ($1.86) earnings per share (EPS) for the quarter, beating the consensus estimate of ($4.41) by $2.55. The business had revenue of $38.25 million for the quarter, compared to analyst estimates of $35.33 million.

Who are Grail's major shareholders?

Top institutional shareholders of Grail include Crcm LP (10.85%), Sessa Capital IM L.P. (8.93%), Primecap Management Co. CA (6.19%) and Baker BROS. Advisors LP (4.85%). Insiders that own company stock include Chun R Ding and Aaron Freidin.
View institutional ownership trends.

How do I buy shares of Grail?

Shares of GRAL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Grail own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Grail investors own include NVIDIA (NVDA), Tesla (TSLA), Advanced Micro Devices (AMD), Meta Platforms (META), Netflix (NFLX), JPMorgan Chase & Co. (JPM) and Visa (V).

Company Calendar

• Last Earnings: 2/20/2025
• Today: 2/22/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Medical laboratories
• Sub-Industry: Healthcare
• Current Symbol: NASDAQ:GRAL
• Previous Symbol: NASDAQ:GRAL
• CUSIP: N/A
• CIK: 1699031
• Web: N/A
• Phone: (650) 771-9796
• Fax: N/A
• Employees: 1,360
• Year Founded: N/A

Price Target and Rating

• Average Stock Price Target: $16.00
• High Stock Price Target: $16.00
• Low Stock Price Target: $16.00
• Potential Upside/Downside: -60.7%
• Consensus Rating: Hold
• Rating Score (0-4): 2.00
• Research Coverage: 3 Analysts

Profitability

• EPS (Most Recent Fiscal Year): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 9.65
• Quick Ratio: 9.65

Sales & Book Value

• Annual Sales: $117.67 million
• Price / Sales: 11.63
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: N/A
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: 33,601,000
• Free Float: N/A
• Market Cap: $1.37 billion
• Optionable: Optionable
• Beta: N/A